These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 10669338)

  • 41. Comparison of HIV type 1 RNA plasma viremia, p24 antigenemia, and unintegrated DNA as viral load markers in pediatric patients.
    Bush CE; Donovan RM; Manzor O; Baxa D; Moore E; Cohen F; Saravolatz LD
    AIDS Res Hum Retroviruses; 1996 Jan; 12(1):11-5. PubMed ID: 8825613
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Experience with the use of immune intravenous immunoglobulin in symptomatic children with human immunodeficiency virus infection].
    Jiménez E; Carrer MT; Pérez Dieppa I; Ortiz L; Fernández M
    Bol Asoc Med P R; 1991 Dec; 83(12):538-42. PubMed ID: 1811606
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Clinical and immunological correlates of immune-complex-dissociated HIV-1 p24 antigen in HIV-1-infected children.
    Duiculescu DC; Geffin RB; Scott GB; Scott WA
    J Acquir Immune Defic Syndr (1988); 1994 Aug; 7(8):807-15. PubMed ID: 7912730
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Passive immunization for the treatment of HIV infection.
    Jacobson JM
    Mt Sinai J Med; 1998 Jan; 65(1):22-6. PubMed ID: 9458680
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Home infusion of intravenous immune globulin in human immunodeficiency virus-infected children.
    Poole JK
    J Intraven Nurs; 1993; 16(1):18-22. PubMed ID: 8437042
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Plasma viremia titration and RNA quantitation in ICD-p24 negative HIV type-1-infected patients.
    Ercoli L; Sarmati L; el-Sawaf G; Cochi S; Lanti T; Iudicone P; Guglielmetti M; Giannini G; Galluzzo C; Tomino C
    AIDS Res Hum Retroviruses; 1995 Oct; 11(10):1203-7. PubMed ID: 8573376
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Human immunodeficiency virus type 1 neutralizing antibodies accelerate clearance of cell-free virions from blood plasma.
    Igarashi T; Brown C; Azadegan A; Haigwood N; Dimitrov D; Martin MA; Shibata R
    Nat Med; 1999 Feb; 5(2):211-6. PubMed ID: 9930870
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cationized hyperimmune immunoglobulins: pharmacokinetics, toxicity evaluation and treatment of human immunodeficiency virus-infected human-peripheral blood lymphocytes-severe combined immune deficiency mice.
    Pardridge WM; Kang YS; Diagne A; Zack JA
    J Pharmacol Exp Ther; 1996 Jan; 276(1):246-52. PubMed ID: 8558438
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Efficient neutralization of primary isolates by the plasma from HIV-1 infected Indian children.
    Prakash SS; Chaudhary AK; Lodha R; Kabra SK; Vajpayee M; Hazarika A; Bagga B; Luthra K
    Viral Immunol; 2011 Oct; 24(5):409-13. PubMed ID: 22004138
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Immunological and virological interactions in patients receiving passive immunotherapy with HIV-1 neutralizing monoclonal antibodies.
    Hinkula J; Bratt G; Gilljam G; Nordlund S; Broliden PA; Holmberg V; Olausson-Hansson E; Albert J; Sandström E; Wahren B
    J Acquir Immune Defic Syndr (1988); 1994 Sep; 7(9):940-51. PubMed ID: 8051620
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Quantitative and qualitative changes in the immunoglobulins of HIV-infected children].
    Alexandrescu R; Diţu S; Găucan E; Cernescu C
    Rev Roum Virol; 1991; 42(3-4):123-33. PubMed ID: 1814429
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Confocal microscopy assessment of lymphoid tissues with follicular hyperplasia from patients infected with human immunodeficiency virus type 1.
    Soontornniyomkij V; Wang G; Kapadia SB; Achim CL; Wiley CA
    Arch Pathol Lab Med; 1998 Jun; 122(6):534-8. PubMed ID: 9625421
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The tolerability and pharmacokinetics of N-butyl-deoxynojirimycin in patients with advanced HIV disease (ACTG 100). The AIDS Clinical Trials Group (ACTG) of the National Institute of Allergy and Infectious Diseases.
    Tierney M; Pottage J; Kessler H; Fischl M; Richman D; Merigan T; Powderly W; Smith S; Karim A; Sherman J
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Dec; 10(5):549-53. PubMed ID: 8548334
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [The use of intravenous 7S immunoglobulins at high doses in HIV-related immunological pathology].
    Fiori GP
    Clin Ter; 1994 Apr; 144(4):301-5. PubMed ID: 8205754
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prevention of HIV infection by passive immunization with HIV immunoglobulin.
    Prince AM; Reesink H; Pascual D; Horowitz B; Hewlett I; Murthy KK; Cobb KE; Eichberg JW
    AIDS Res Hum Retroviruses; 1991 Dec; 7(12):971-3. PubMed ID: 1812946
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Intravenous immune globulin for the prevention of infections in children with symptomatic human immunodeficiency virus infection.
    Mofenson LM; Moye J
    Pediatr Res; 1993 Jan; 33(1 Suppl):S80-7; discussion S87-9. PubMed ID: 8433880
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Variability and prognostic values of virologic and CD4 cell measures in human immunodeficiency virus type 1-infected patients with 200-500 CD4 cells/mm(3) (ACTG 175). AIDS Clinical Trials Group Protocol 175 Team.
    Lathey JL; Hughes MD; Fiscus SA; Pi T; Jackson JB; Rasheed S; Elbeik T; Reichman R; Japour A; D'Aquila RT; Scott W; Griffith BP; Hammer SM; Katzenstein DA
    J Infect Dis; 1998 Mar; 177(3):617-24. PubMed ID: 9498440
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparison of the frequencies and levels of human immunodeficiency virus type 1 markers in specimens from chronically infected human T-lymphocyte cultures and from patients.
    Witt DJ; Ginocchio CC; Wang XP; Kaufman MK
    Clin Diagn Lab Immunol; 1999 May; 6(3):369-76. PubMed ID: 10225838
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [One antibody preparation is not another: the role of passive immunotherapy in the treatment of HIV infection].
    Leverstein-van Hall MA; Goudsmit J
    Ned Tijdschr Geneeskd; 1995 Feb; 139(7):316-20. PubMed ID: 7877699
    [No Abstract]   [Full Text] [Related]  

  • 60. Passive hyperimmune therapy: a viable treatment option for the patient with acquired immune deficiency syndrome.
    Raven NC
    J Intraven Nurs; 1994; 17(4):214-6. PubMed ID: 7965365
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.